Ritonavir: Difference between revisions
David Canner (talk | contribs) No edit summary |
David Canner (talk | contribs) No edit summary |
||
| Line 5: | Line 5: | ||
* Drug Class: [[HIV Protease]] Inhibitor | * Drug Class: [[HIV Protease]] Inhibitor | ||
* Date of FDA Approval (Patent Expiration): 1996 (2013) <br /> | * Date of FDA Approval (Patent Expiration): 1996 (2013) <br /> | ||
* 2009 Sales: $310 Million | * U.S. 2009 Sales: $310 Million | ||
* Importance: It is a powerful [[HIV Protease]] inhibitor. It is a major component of most HIV combination therapies because of its potent inhibition capacity of CYP3A4, increasing the bioavailability of other viral inhibitors. | * Importance: It is a powerful [[HIV Protease]] inhibitor. It is a major component of most HIV combination therapies because of its potent inhibition capacity of CYP3A4, increasing the bioavailability of other viral inhibitors. | ||
* The following is a list of Pharmacokinetic Parameters. See: [[Pharmaceutical Drugs]] for more information | * The following is a list of Pharmacokinetic Parameters. See: [[Pharmaceutical Drugs]] for more information | ||